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Abstract
In recent years, breast surgeons have been increasing the use of ultrasound as a 
reliable and useful tool in their practice to assist in managing patients and the oper-
ating room. An appropriate clinical and sonographic correlation can define diag-
nostic workup, provide immediate reassurance to the patients, and perform one-site 
diagnostic needle interventions. Particularly, it has a significant role in low-middle 
income countries, where imaging services are scarce due to its high cost, main-
tenance needs, and limited availability of trained personnel. Therefore, training 
and accreditation of surgeons who perform and interpret ultrasound are required 
interventions to influence the provider’s knowledge, accomplish optimal practices, 
complete diagnostic examinations of the breast, and improve the patients’ quality 
of care. This review aims to serve as an educational resource regarding the up-to-
date value of breast ultrasound for surgeons.
Keywords: Breast Ultrasound, Breast Imaging, Interventional Radiology,  
Breast Cancer, Intraoperative Ultrasound, Low and Middle Income Countries, Breast 
Surgeon
1. Introduction
Ultrasound (US) is a reliable and helpful tool in evaluating, diagnosing, and man-
aging breast disease improving the patients’ quality of care. In recent years, with the 
increasing quality of the ultrasonography equipment, the surgeons have escalated its 
use, particularly by breast surgeons in their clinical practice and operating room, which 
has led to the enhanced provision of care for women with breast disease [1, 2].
Breast ultrasound allows immediate identification and characterization of 
localized breast symptoms, palpable abnormalities noted on physical breast 
examination; and nonpalpable abnormalities identified on other breast imaging 
modalities. Hence, an appropriate clinical and sonographic correlation can define 
diagnostic workup, provide immediate reassurance to the patients, and perform 
one-site diagnostic needle interventions. In addition, it has the advantages of being 
low-cost, more affordable, portable, safe, and requires minimal maintenance. It 
has a significant role in low-middle income countries, where imaging services are 
scarce due to its high cost and limited availability of trained personnel [3]. In these 
settings, capacities on local referral chains are minimal; therefore, the use of US by 
breast surgeons offers significant appropriateness to the patients by allowing them 
to obviate the high threshold needed to reach referral services.
Breast surgeons can acquire comprehensive skills and competence in US tech-
niques and their indications in the outpatient setting under the supervision of a 
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US-experienced radiologist or surgeon, enhancing the multidisciplinary care of 
breast patients. Also, participation in training courses guided by local proficiency 
standards [1] allows the successful incorporation of breast ultrasound and ultra-
sound-guided breast procedures into clinical practice, which can then be translated 
into the operation room. Training and accreditation of surgeons who perform and 
interpret ultrasound is an intervention that influences providers’ behavior for opti-
mal patient outcomes. Hence, the surgeon who assists in managing breast patients 
has to design a rational plan of action based on their knowledge, available resources, 
and patient needs to ensure adequate and safe breast care [4–6].
The purpose of this review is to serve as an educational resource for the value 
of breast ultrasound in the clinical practice of the surgeon by providing the under-
standing of its applications for the evaluation, management, and monitoring of 
breast diseases; and the recognizing of its indications for interventional breast pro-
cedures in order to improve the decision-making process and enhance patient care.
2. Indications of breast ultrasound
Breast ultrasound is valuable in several clinical situations, including but not 
limited to the following [4, 5, 7]:
• Identification and characterization of localized breast symptoms, palpable 
abnormalities noted on clinical breast examination, and nonpalpable abnor-
malities identified on other breast imaging modalities.
• Initial Imaging evaluation of localized breast symptoms and palpable abnor-
malities in patients under 40 years of age who are not at risk of developing 
breast cancer and in lactating or pregnant women.
• Evaluation and characterization of abnormalities associated with breast 
implants.
• Guidance for breast interventional or surgical procedures.
• Preoperative evaluation of the breast and axilla in diagnosed breast cancer.
• Evaluation and assessment of the breast after surgical or medical therapy.
• Intraoperative ultrasound-guided breast surgery and intraoperative assessment 
of lumpectomy margins.
3. Breast ultrasound overview
Breast Ultrasound is a diagnostic tool that makes the whole imaging assessment 
more specific and expedited. Alongside clinical information, US characterization 
allows imaging correlation to define further imaging workup and recommend inter-
ventional procedures for diagnostic and therapeutic purposes. Ultrasound is called 
hand-held or manual when the probe is manually moved on the breast surface 
(HHUS). In automated whole breast ultrasonography (ABUS), the probe scans the 
whole breast in a standard fashion, gathering and storing a set of images for later 
review by physicians interpreting the findings [8].
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3.1 Reporting system
The Breast Imaging Reporting and Data System® (BI-RADS®) is a manage-
ment system developed for imaging that contains: (1) a lexicon of descriptors, i.e., 
a dictionary of specific imaging features; (2) a standardized reporting structure-
including final assessment categories with accompanying recommendations; (3) a 
framework for data collection and auditing. This system aids communication and 
comprehension of imaging findings by all members of the multidisciplinary breast 
care team: surgeons, pathologists, oncologists, radiologists, and other health care 
providers. BI-RADS final assessment categories and their recommendations have 
become the standard by which physicians determine breast care, allowing uniform 
drafting of reports, facilitating the research, and performance evaluation [9].
These categories, currently are as follows [10]:
• Category 0: Incomplete. Need additional imaging evaluation or previous 
images for comparison to determine appropriate management and final 
assessment.
• Category 1: Negative. There is no US imaging abnormality. Routine screening.
• Category 2: Benign Findings. Negative for malignancy. No further investigation 
is required based on the imaging finding. Routine screening.
• Category 3: Indeterminate/Probably Benign Finding. Lesions with less than 2% 
risk of malignancy. Should recommend initial short-interval follow-up.
• Category 4: Suspicious Abnormality. Lesions with >2% but <95% likelihood of 
malignancy. Diagnostic tissue sampling through biopsy should be performed 
in the absence of clinical contraindication— 4A (low suspicion for malignancy, 
>2% but ≤10% likelihood of malignancy), 4B (moderate suspicion for malig-
nancy, >10% but ≥50% likelihood of malignancy), and 4C (high suspicion for 
malignancy, >50% but <95% likelihood of malignancy).
• Category 5: US findings highly suggestive of malignancy. More than 95% 
likelihood of malignancy. Diagnostic tissue sampling through biopsy should be 
performed in the absence of clinical contraindication.
• Category 6: Known biopsy-proven malignancy. Reserved for US examinations 
performed for cancer staging or monitoring of neoadjuvant therapy.
Similarly, in the UK, the Royal College of Radiologists Breast Group (RCRBG) 
[11] has developed a five-point scoring system to classify breast images, using 
a similar rationale to the American College of Radiologists’ development of the 
BI-RADS®. However, this classification does not specify the probable cancer risk of 
each category. This five-point system is Normal (category 1)- there are no signifi-
cant imaging findings. Benign findings (category 2)- the benign imaging findings 
are not indicated for further investigation. Indeterminate / probably benign (cat-
egory 3)- low risk of malignancy, and further investigation through needle biopsy 
is indicated. Findings suspicious of malignancy (category 4)- show a moderate risk 
of malignancy, so further investigation is indicated through a needle biopsy. Highly 
suspicious findings of malignancy (category 5)- high risk of malignancy; further 
investigation is indicated through a needle biopsy.
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3.2 Imaging quality
The US is a highly operator-dependent technique due to a lack of repetitiveness 
and a strong reliance on specialists’ abilities and judgment to capture the right 
image to be documented in the report. Although the ACRIN 6666 trial has proposed 
a model, no standard US acquisition technique exists yet [12]. A specialist with 
competence and experience should perform breast ultrasound [13, 14], correlating 
clinical signs or symptoms, mammographic studies, and other breast imaging. If 
the ultrasound has been performed previously, the current examination should be 
compared with a previous ultrasound, as appropriate.
3.3 Setting
The correct application of the vocabulary depends on the quality of the ultra-
sound equipment, ultrasound technique, and an adequate compression of the breast 
anatomy. Breast ultrasound should be performed with high-resolution linear array 
transducers from 7.5–8 (at least) to 15–18 MHz. Higher frequency is recommended 
for less depth penetration (superficial details or small breasts). Lower frequency 
should be used for deeper areas or very large breasts (4 to 8 MHz) [5]. An acoustic 
stand-off pad is useful for superficial images. It is critical to document and capture 
appropriate imaging for actionable cases by optimizing focal zone selections, gain 
settings, and view fields. When a potential finding is located, turn the transducer to 
assess if it persists and better characterize it. A wide-band linear matrix transducer 
offers better resolution by focusing on the short axis.
3.4 Positioning
The patient should be lying in the supine position placed with the chest 
undressed. There are two breast survey patient positions: a medial position with the 
ipsilateral arm overhead or with arms flexed behind the head to flatten the breast, 
and an oblique position with a wedge supporting the back for scanning the lateral 
part of the breast and the axilla. Scan techniques should allow systematic explora-
tion of the entire breast, whether grid scanning or radial scanning patterns.
3.5 Labeling
Images should be labeled as right or left breast and should be reported the transducer 
orientation. The localization of the findings is described by quadrant -upper external, 
lower external, lower internal, upper internal- and retroareolar region; or according to 
the clock-wise position (distance from the nipple). Distance from the nipple to the lesion 
should not be measured from the areola’s edge since the areolar width is variable [5]. A 
large lesion can be captured in a single image by Panoramic Imaging (Extended Field of 
View –FOV-) and traced the lesion back to the nipple for an accurate distance reporting.
3.6 Measurements
All lesions are measured in three dimensions, including length, width, and height 
unless shadowing disguises the accurate height measurement. Dimensions must 
register with the greatest millimeter or centimeter accuracy. The first measurement 
represents the longest axis. The following measurement is perpendicular to the long 
axis, and the last measurement is from an orthogonal projection to the first image 
(representing a different plane from the former two images). It is necessary to 
capture two sets of lesion images (one with calipers and one without) [6, 10].
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Solid masses diagnosed as benign pathology may safely have periodic surveil-
lance if the volume growth rate is less than 16% per month in women under 50 years 
and less than 13% per month in women 50 years or older. An acceptable mean 
change for three dimensions during a six-month interval is 20% for all ages [15].
3.7 Documentation
Accurate documentation is essential for high-quality patient care. Ultrasound 
report is only as good as the images on which it is based. Images and reports are part 
of the patient’s medical record. Each image should have the facility name, date of 
examination, patient’s first and last name, identification number, and birth date. 
It should display identification of left or right breast and lesion’s location. It should 
indicate transducer orientation within the breast (radial, antiradial, oblique, trans-
versal, or sagittal), distance from the nipple, and three orthogonal measurements. 
Breast ultrasound document must contain the following sections [5, 6, 10]:
• Indication of breast ultrasound.
• Description of the scope and technique of breast ultrasound.
• Brief description of the overall composition of the breasts.
• A detailed description of important findings.
• Comparison with prior relevant imaging studies and correlation with signs 
observed during the clinical examination.
• Assessment and management recommendations.
• Report of ultrasound-guided interventional procedures should include the 
location of the lesion, the approach, the type of prep and local anesthesia, 
the skin incision, the type of device used, the number of cores taken, and the 
type of clip placed, if any. Whenever specimen radiographs or sonograms are 
performed, they should be recorded in the report.
4. Breast ultrasound lexicon
Descriptors for breast tissue composition (background echotexture) are correlated 
to mammographic breast densities. These are homogeneous-fat, homogenous-
fibroglandular, and heterogeneous. In Homogeneous-fat background, fat lobules and 
echogenic bands of supporting structures comprise the bulk of the breast tissue. In 
the Homogeneous-fibroglandular background, a dense zone of the homogeneously 
echogenic bands of fibroglandular parenchyma is present beneath the thin hypoecho-
genic layer of fat lobules. Heterogeneous background echotexture is characterized by 
multiple small areas of increased or decreased echogenicity, either focal or diffuse.
For the identification and characterization of the masses, the number of char-
acteristics to be described are seven: shape (oval, round, and irregular), orientation 
(parallel and not parallel), margins (circumscribed and not circumscribed, indistinct, 
angular, microlobulated, and spiculated), echo pattern (anechoic, hyperechoic, 
complex cystic and solid, hypoechoic, isoechoic and heterogeneous) posterior acoustic 
features (no posterior acoustic features, enhancement, shadowing and combined pat-
tern), calcifications (in or outside of a mass, and intraductal) and associated features.
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Associated features include architectural distortion; edema; duct changes; skin 
changes (skin retraction, skin thickening-focal and diffuse-); vascularity (absent, 
internal, and vessel in rim), and elasticity assessment. Elasticity assessment of tis-
sue stiffness (elastography) explores modifications of the US image of a lesion after 
applying a manual compression (strain) or introducing ultrasonic energy (shear 
wave). Applicable descriptors are color-codes tissue hardness. The elasticity assess-
ment is a feature available on many modern US units and included in the last BI-RADS 
edition. The World Federation of Ultrasound in Medicine and Biology (WFUMB) has 
published guidelines in characterizing breast lesions as benign or malignant, although 
this fact cannot be misinterpreted as an entire endorsement of the clinical validity 
of elasticity assessment. Therefore, the elastography should be integrated for patient 
management alongside the more predictive ultrasonic morphologic features of malig-
nancy (shape, margin, and echogenicity). Currently, the share-wave elastography is 
used as a valuable preoperative predictor of chemotherapy response [16].
It is essential to analyze several features, rather than just one, for lesion catego-
rization as benign or malignant. Benign and malignant solid masses can equally be 
well-differentiated on ultrasound. Benign US features include an oval shape, well-
circumscribed margins, and parallel orientation to the skin. Suspicious US features 
include irregular margins, marked hypoechogenicity, post-acoustic shadowing, and 
non-parallel orientation to the skin (Figure 1).
5. Identification and characterization of palpable breast symptoms
5.1 Nipple discharge
Clinical workup of nipple discharge includes a detailed patient medical history, 
recently recorded trauma, careful physical examination, and the most suitable 
breast imaging modality. The evaluation and management aim of nipple discharge 
is to identify the causative condition accurately, distinguishing between “patho-
logic” causes from those with “benign or physiological” causes, and consequently 
diagnosing cancer when it is present.
The discharge’s clinical characteristics should describe color, whether uni or 
bilateral or associated with nipple stimulation or breast compression, whether it 
originated from a single duct or multiple ducts [17]. Benign nipple discharge is 
traditionally considered bilateral, non-spontaneous, emanating from multiple ducts 
Figure 1. 
Ultrasound characteristics of breast lesions. (a) Circumscribed, oval, anechoic mass with parallel orientation 
and posterior enhancement consistent with a simple cyst. (b) Circumscribed, round, heterogeneous mass with 
lateral shadowing. The pathological diagnosis by biopsy was Fibroadenoma. (c) Irregular, noncircumscribed, 
hypoechoic mass with posterior shadowing: Invasive Breast Carcinoma by biopsy.
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after manipulation or stimulation; varies in color from white to yellow to green to 
brown. Pathologic discharge is considered unilateral, spontaneous, persistent, clear, 
serous, serosanguinous, or bloody from a single duct [18].
Breast imaging identifies and characterizes any lesion in these patients and 
assists subsequent percutaneous biopsy in achieving a histopathologic diagnosis 
[19]. Magnetic resonance imaging (MRI) may be useful in pathologic nipple 
discharge when lesions cannot be localized with other diagnostic imaging [20]. 
However, MRI is limited, and it is not yet a generalized practice because it is expen-
sive and not readily available in all areas [21].
In patients with nipple discharge, the sensitivity of mammography in detecting 
an abnormality is low. The ability of mammograms to identify intraductal lesions is 
limited since they are generally small and lack microcalcifications. In mammogra-
phy subareolar region usually shows increased density. The sensitivity and specific-
ity of ultrasound vary from 36 to 83% and 12–84%, respectively. Several factors 
can explain this wide range, including differences in the criteria used to distinguish 
between pathologic from benign discharge and differences in ultrasound technol-
ogy employed [22]. Breast US is useful for visualizing ductal structures, localization 
of the lesions that cause the nipple discharge, and the subsequent accomplishment 
of imaging-guided percutaneous biopsy to determine whether a malignant lesion 
is the cause of the pathologic nipple discharge. US-guided core needle biopsy in 
patients with pathologic nipple discharge, who had negative findings on mammog-
raphy but had positive findings on US have reported 15.1% of cancer detection [23].
Breast US is capable of visualizing ductal structures located in the subareolar 
region. The BI-RADS® categorizes ductal changes as associated features. Duct 
changes are manifested by:
• cystic dilatation of a duct or ducts comprising irregular calibers or arboriza-
tion. Dilated retroareolar duct is defined as duct ectasia, i.e., a duct with a 
diameter over 3 mm;
• extension of ducts to or from a malignant lesion; or
• intraductal mass, thrombus, or debris. Intraductal masses are assessed as 
category 4a, pointing out a requirement for biopsy because these have a risk of 
malignancy that cannot eliminate (Figure 2) [10, 24].
Figure 2. 
(a) Single galactophere duct ectasia without any filling defect (calipers); (b) 49-year-old female with uniorificial 
serous nipple discharge. US: duct ectasia with echogenic content filled with thick secretion; (c) 46-year-old female 
with uniorificial bloody nipple discharge. US: single dilated duct with isoechoic endoductal mass with an ill-defined 
outline representing an intraductal papilloma by pathology report; (d) 39-year-old female with right uniorifical 
serosanguineous discharge. US: irregular intraductal mass arising from a dilated duct due to carcinoma in situ.
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At present, there are no clear guidelines on which radiographic or clinical vari-
ables in patients with nipple discharge can predict malignancy. The malignancy rate 
in patients with nipple discharge ranges from 9.3–23% [18, 25–29]. However, these 
data were derived from studies made before improvements in breast ultrasound and 
the imaging-guided percutaneous biopsy. Most studies included patients referred 
to surgery departments or specialty breast centers [18, 25–27] or only those who 
underwent duct excision [28, 29].
Currently, less invasive diagnostic procedures affect the decision-making process 
about surgical management. For patients with pathological discharge and negative 
imaging evaluation (negative mammography results and negative features on breast 
US), surgical treatment has traditionally been indicated to eliminate symptoms and 
rule out breast carcinoma [24–28]. Although based on the low risk of underlying 
carcinoma, several studies have proposed conservative clinical follow-up and have 
shown that short-term monitoring would appear to be a reasonable approach in 
these patients [30, 31] Sabel et al. [31] suggested short-term observation with repeat 
imaging and clinical exam for low-risk patients (those without a strong family 
history or personal history of cancer). Ashfaq et al. [30] proposed a close clini-
cal follow-up comprising a physical examination and breast ultrasound every six 
months for 1 to 2 years, or until the discharge resolved, whichever came first, plus 
annual mammography according to the screening guidelines. Patients who refuse 
to watch and wait as a clinical approach or report discomfort by the symptom or 
discharge after two years should consider the surgical treatment (Figure 3).
5.2 Inflammatory breast disease
Ultrasound examination is essential in evaluating patients with breast inflam-
mation to identify fluid collections in the affected area by the inflammatory 
Figure 3. 
Workflow for the management of women presenting with nipple discharge.
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process and distinguish between cancer-related and non-cancer-related breast 
inflammation (since their clinical presentation can be misleading). Inflammatory 
breast disease manifests clinically by the cardinal signs of inflammation: redness, 
heat, and pain. It is classified as an infectious origin (generally bacterial) or non-
infectious origin.
Breast US cardinal signs of infectious inflammatory breast disease are [32]:
• Skin thickening.
• Reticulated network of irregular hypoechoic lines, located at the interface 
between the dermis and subcutaneous fat, representing either dilated lym-
phatics or interstitial fluid.
• Increased echogenicity of surrounding fat tissue. Hyperechoic area extension is 
variable and depends on the degree of inflammation.
• Subcutaneous dilated vessels. Doppler signal demonstrates increased vascular-
ity associated with hyperemia.
• Reactive lymphadenopathy: Enlarged axillary lymph nodes, regular cortical 
thickening, smooth borders, and visible central hilum.
• Ductal ectasia with thickened walls and echoic content into the duct 
(Galactophoritis).
• Breast abscess presents as round, oval or irregular; generally hypoechoic with 
multiples internal echoes, sometimes with fluid-debris level; usually with pos-
terior acoustic enhancement. The walls may appear thickened with indistinct 
margins to the surrounding hyperechoic fat. An evident hypoechoic sinus tract 
probably extends the skin surface (Zuska’s disease) [33]. It is a rare disease 
characterized by repeated and recurrent episodes of inflammatory abscesses 
and fistulae that is usually open on the edge of the areola or in the breast tissue 
close to it.
Ultrasound can be used to guide percutaneous sampling procedures and 
 complete drainage of the fluid collection. If the collection is large (sizes >3 cm)- or 
if it remains or recurs-placing a percutaneous drainage catheter guided by US is the 
optimal course of the management [34]. In the unusual event of inadequate percu-
taneous drainage, surgical drainage should be an option.
Non-infectious inflammatory breast disease includes Granulomatous Mastitis 
and Diabetic Mastopathy. Diabetic Mastopathy appears as a hypoechoic mass with 
ill-defined margins and marked posterior shadowing.
Granulomatous Mastitis is a diagnosis of exclusion, and it is hardly made based 
on clinical signs and imaging findings. Clinical presentation is a firm to hard mass 
localized or diffused involvement of the entire breast with skin thickening, ery-
thema, and inflammation (peau d’ orange) that can clinically mimic carcinoma. 
In addition, the presence of draining sinus tracts and regional adenopathy are 
frequent. The diagnosis is established by histological analysis showing a granulo-
matous inflammatory response containing multinucleated giant cell granuloma. It 
is mainly seen in developing countries [35, 36]. Breast US signs in granulomatous 
mastitis are:
• Skin thickening
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• Heterogeneously hypoechoic mass with poorly defined borders, with internal 
tubular hypoechoic structures.
• Parenchymal heterogeneity and architectural distortion with or without 
acoustic shadowing in the absence of a definite mass. Increased surrounding 
parenchymal vascularity on Doppler ultrasound.
• Enlarged axillary lymph nodes with reactive cortical thickening.
• Fluid collections with low-level internal echoes and hypoechoic sinus tracts 
extending to the skin in advanced cases (Figure 4).
5.3 Mass in breast skin
Lesions in the breast skin that arise within the dermal layer are considered 
generally benign. Most dermal lesions are palpable, providing the reason for 
imaging evaluations. Although occasionally, they are detected at screening 
imaging. This lesion includes dermal cysts, specifically sebaceous cysts and 
epidermal inclusion cysts (after a mammoplasty), for which routine surveillance 
is recommended..
Ultrasound findings of dermal lesions are [37]:
• An echogenic dermal layer surrounds lesions.
• A tract-to-skin from the lesion represents an extension of the hair follicle from 
the dermis through the epidermis.
• An acute or right angle (90 degrees) with the dermal line. A claw of hyper-
echoic tissue wraps around the lesion’s margin.
• Round well-circumscribed nodule or non-circumscribed-when inflammation 
is present-depending on its contents. The internal echotexture varies from 
anechoic to hypoechoic and heterogeneous (Figure 5).
Figure 4. 
45-year-old female with redness, heat, and pain in the right breast. US: (a) Hypoechoic mass with 
heterogeneous content, poorly defined borders, and acoustic shadowing. Thickening of the dermal layer. 
Fat hyperechogenicity around the mass. (b) Image using Doppler signal reveals increased surrounding 
vascularization. (c) US-Guided Percutaneous Biopsy: Granulomatous Mastitis.
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6.  Evaluation and characterization of abnormals associated  
with implants
In addition to the clinical examination, ultrasound is a useful diagnostic test to 
examine breast implant alterations, mainly ruptures. The breast implant is anechoic 
with an echogenic shell of a three-layered appearance (an anechogenic line between 
two echogenic lines). Small radial folds and a small amount of periprosthetic fluid 
are considered normal findings. US is very specific in evaluating breast implant 
integrity, albeit not very sensitive. The probability of rupture is highly suspected in 
US, but a rupture is still possible, even if it cannot be visible in US [7].
Alterations of the implant structure, classically, are capsular contracture or cap-
sular fibrosis and ruptures. Capsular contracture is the capsule developed around the 
implant as the body’s overreaction to a foreign device, leading to the hardening and 
deformation of the implant. There are three typical findings for capsular contrac-
ture or fibrosis: (1) deformity, not well evaluable with ultrasound (due to the narrow 
field of view), (2) increased number of radial folds, creating an undulated implant 
surface; and (3) thickening of the fibrous capsule, an echogenic line superficial to the 
implant shell, separated only by an anechoic line [38].
Ruptures are subdivided into intracapsular (implant envelope is broken, but 
containment remains inside the capsule) and extracapsular (when containment leaks 
out of the broken capsule) type [39]. The classic finding of extracapsular rupture of 
silicone implant on US is the snowstorm appearance, i.e., a highly echogenic pattern of 
scattered and reverberating echoes with a well-defined anterior margin. This appear-
ance can also see in the axillary nodes containing free silicone. Intracapsular silicone 
implant rupture finding is the stepladder sign, characterized as a sequence of horizon-
tal echogenic straight or curvilinear lines inside the collapsed implant shell [40]. If the 
prosthesis is saline, the collapsed implant shell will be evident by ultrasound.
According to the American College of Radiologists [41], breast implants 
evaluation varies on patient age, implant type, and symptoms. For patients less 
than 30 years with rupture of saline implants, ultrasound is the imaging choice. 
Mammography or US may be used for patients from 30 to 39 years of age with 
rupture of saline implants, and mammography is preferred for those 40 years and 
older. MRI without contrast or US is preferred for patients less than 30 years with 
Figure 5. 
57-year-old female with epidermal inclusion cyst located on the breast skin after mammoplasty. US: (a) 
hypoechoic well-circumscribed mass contained within the dermis. The dermal layer is thickened (white arrow) 
and extended into the hypodermis. A tract extends to the epidermal skin surface (red arrow). (b) The claw sign 
(white dashed line): dermal tissue wrapping around the margin of the lesion forming an acute angle.
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rupture of silicone implants. MRI without contrast, mammography, or US may be 
used for those 30 to 39 years of age, and for those 40 years and older, MRI without 
contrast or mammography is used. Patients with unexplained axillary lymphade-
nopathy and silicone implants (current or previous) are assessed with the axillary 
US. Patients with suspected breast implant-associated anaplastic large-cell lym-
phoma should be recommended breast US, regardless of age or implant type.
7. Guidance for percutaneous and interventional procedures
Interventional breast procedures are guided by the clinical examination or 
image-detected nonpalpable breast abnormalities to characterize the lesion 
histologically and plan therapeutic management [11]. Clinical guidance may be 
sufficient in palpable lesions, but image-guided biopsy allows more precise acquisi-
tion with high diagnostic accuracy. Ultrasound-guided procedures are accessible 
without needing ionizing radiation or intravenous contrast but are rather minimally 
invasive and less expensive than surgical biopsies [42].
Training and accreditation of surgeon-performed US are essential steps for 
increasing the use of percutaneous biopsy to diagnose breast pathologies, avoid-
ing additional surgeries and diagnostic delays, particularly in resource constraint 
settings. Breast surgeons, who perform the percutaneous biopsy, must understand 
its indications, have technical skills for performing them, and be experienced 
operators to avoid misleading and harmful procedures, resulting in missed cancer. 
They should record complications and adverse events during ultrasound-guided 
interventional procedures and regularly review them to recognize circumstances 
and opportunities to improve patient management quality. In the same way, sur-
geons should monitor false-negative rates and inadequate tissue samples of these 
interventional procedures to audit their practice [9].
US-Guided interventional procedures include fine-needle aspiration cytology 
(PAAF), core needle biopsy (CNB), vacuum-assisted needle biopsy, placement of 
brachytherapy devices, and breast tissue ablation.
7.1 US-guided fine-needle aspiration cytology (US-FNAC)
FNAC uses a disposable needle (usually 18 to 27- gauge) connected to a vacuum 
syringe. It is technically simple, widely available, and easy to plan in outpatient clin-
ics. It can be performed with a low risk of complications. It is an accurate technique 
and affordable in resource constraints settings [43]. Quality depends on the aspira-
tor’s competence and the pathologist’s proficiency and expertise in determining its 
interpretation. FNAC is more appropriate for patients on anticoagulants for lesions 
adjacent to the skin, close to the chest wall or close to vessels, or patients with 
implants, or with very small lesions and those with small/thin breasts [44].
Ultrasound-guided needle aspiration puncture is mainly recommended for 
the aspiration of simple symptomatic cysts. If the aspiration fluid is clear, yellow, 
greenish-black (no atypical features), it can be discarded and not require further 
evaluation [45]. In case that the fluid is bloody, it must be sent for cytological analy-
sis. If it looked purulent, it must be sent for culture and gram stain. If suspicious, 
atypical, or mucin results are found in cytology, re-biopsy or excision of the lesion 
should be performed. The patient should accomplish a follow-up ultrasound in 4 to 
6 weeks when the cyst has been completely evacuated. Whether the cyst recurs, the 
re-biopsy of the lesion is mandatory [46].
Although core needle biopsy is currently advocated as the standard procedure 
in most breast centers in developed countries, FNAC continues to be an acceptable 
13
Value of Breast Ultrasound in the Clinical Practice of the Surgeon
DOI: http://dx.doi.org/10.5772/intechopen.100520
and reliable procedure for diagnosing suspicious breast lesions in low and middle-
income countries. Two meta-analyses assessed the accuracy performance of FNAC 
[46, 47]. The meta-analysis of Yu et al. [48] included 46 studies showing pooled 
sensitivity of 92.7% and specificity of 94.8%; however, the pooled sensitivity and 
specificity for eleven studies that reported unsatisfactory samples was 92.0% and 
76.8%, respectively. The meta-analysis by Wang et al., [47] compared the sensitivity 
and specificity of CNB and FNAC in twelve studies; the pooled analysis showed 
that the sensitivity of CNB is better than that of FNAC (87% vs. 74%). However, the 
specificity of CNB was similar to that of FNAC (98% vs. 96%).
7.2 Ultrasound-guided core needle biopsy (CB)
Ultrasound-Guided Core Needle Biopsy involves 14G–16G spring-loaded auto-
mated needles with an excursion throw that allows small cylinders of tissue (speci-
men) to be cut and collected within the notch of the needle. The needle is extracted 
from the breast to recover the breast tissue and then re-inserted for further samples. 
False-negative rates range from 0% [49] to 9% [50], and underestimation rates 
range from 3.4–100% in atypical ductal hyperplasia, radial scars, papillary lesions, 
lobular carcinoma in situ (LCIS), and phyllodes tumors [51].
7.3 US vacuum-assisted biopsy (VAB)
VAB is commanded with suction and a rotating cutter. This device uses needles 
ranging from 7 G to 12 G. Vacuum aspiration pulls lesion tissue samples for col-
lection into a sampling window without removing the needle from the biopsy site 
[50]. VAB is commanded with suction and a rotating cutter. This device uses needles 
ranging from 7 G to 12 G.
Currently, there is an increasing interest in using US-guided vacuum-assisted 
devices for the complete removal of a probably benign lesion [52, 53], with low 
rates of residual masses, particularly for lesions <1 cm in size [54]. Additionally, 
successful excision of intraductal masses has been reported in women with nipple 
discharge [55].
7.4 Guided ablative techniques
Tumor destruction techniques are by heat (hyperthermia) or by cold (cryother-
apy) means. Several technologies using hyperthermia are available: radiofrequency, 
microwaves, interstitial laser, and electroporation [42]. The percutaneous radio-
frequency device utilizes five small radiofrequency-enabled wires deploy from the 
wand (capture basket) to circumscribe the lesion. Radiofrequency passes through 
the expanded basket, sectioning and coagulating the breast tissue. The device can 
remove entire lesions up to 25–30 mm [56].
Cryotherapy involves the use of argon gas to generate an ice sphere around 
the lesion. Ultrasound is used in real-time to visualize the growth of the ice ball 
around the lesion; this is an outpatient procedure that can be performed under local 
anesthesia [2].
7.5 Indications for excisional biopsy
Currently, the percutaneous imaging-guided biopsy is the standard for the 
diagnosis of most breast lesions. However, there are still indications when excisional 
surgical biopsy should be recommended. The acquaintance of such indications is 
essential to adopt the multidisciplinary approach and provide the best patient care. 
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Adequate radiology/histology/clinical correlation is essential, in addition to the cau-
tious post-biopsy surveillance for immediate detection of false-negative results, to 
prevent delays in cancer diagnosis. Clinical situations where open excisional biopsy 
should be recommended include [57]:
• Discordance between imaging findings and histopathology.
• Suspicious interval changes in a lesion previously diagnosed as benign pathology.
• High-Risk Lesions: Atypical Ductal Hyperplasia; Lobular carcinoma in Situ; 
Atypical Lobular Hyperplasia.
• Flat epithelial atypia, radial scar, or radial sclerosing lesion.
• Papillary lesions with atypia. Columnar alteration with cytologic atypia.
• Lesions not amenable to percutaneous biopsies include lesions close to the 
chest wall or immediately adjacent to the implant, inadequate breast tissue, 
patient intolerance to lie flat, and lesions superficially located within the skin.
• Lack of adequate retrieval of calcifications (as judged by the radiologist) when 
calcifications are targeted.
8. Preoperative evaluation of the breast in diagnosed breast cancer
The tumor size obtained by imaging is an important factor in the preoperative 
planning of breast cancer, whether it is the type of surgery or whether it initiates 
with neoadjuvant chemotherapy (NAC). Thus, mammography has been consid-
ered the standard imaging tool for detecting and assessing tumor size. Currently, 
the high-resolution US and MRI have been included in the diagnostic flowchart 
to achieve higher sensitivity [56], underscoring the surgeons’ need to know the 
accuracy of each test to attain affordable breast cancer patient care.
Several studies [57–68] assess mammography, US, and MRI accuracy for 
measuring preoperative tumor size in patients who do not receive neoadjuvant 
chemotherapy. These studies showed correlations between ultrasonographic tumor 
size and pathologic tumor size ranging from 0.40 to 0.93, suggesting that breast 
ultrasound accurately predicts tumor size for those patients.
Although many studies have evaluated the value of preoperative magnetic 
resonance imaging (MRI) in invasive breast cancer, its role in clinical practice is still 
controversial, failing to show surgical outcome benefits [69–71]. A meta-analysis 
by Houssami and colleagues [69], which included 3,112 patients with breast cancer, 
found a significant increase in mastectomy rates in the MRI group (16.4% and 
25.5%, respectively) with the non-MRI group (8.1% and 18.2%, respectively). 
This meta-analysis failed to show a surgical outcome benefit because there was no 
difference in re-excision rate following an initial breast-conservation, with 11.6% 
in the MRI group compared with 11.4% non-MRI group (P = .87). The authors 
suggest that a routine MRI in breast cancer patients could do more harm than 
good by identifying foci of disease beyond the lumpectomy bed that would have 
been eradicated by adjuvant radiation. Two prospective randomized trials [70, 71] 
assessed the effect of MRI on surgical outcomes in patients with breast cancer, with 
a primary end-point of reoperation rates (re-excision and conversion to mastec-
tomy). The United Kingdom (UK) randomized trial (COMICE) [70] evaluated the 
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role of breast MRI in 1,625 women who had recently been diagnosed with primary 
breast malignancy. The trial showed no significant difference in the reoperation rate 
between the MRI group (18.7%) and the non-MRI group (19.3%). A twenty-eight 
percent increase in mastectomy rates was considered pathologically avoidable in 
the MRI group. The MONET trial [71] randomized 418 women with a nonpal-
pable suspicious mammographic or sonographic finding (BIRADS 3 to BIRADS 5 
lesion) to receive preoperative MR Imaging versus usual care (mammography and 
ultrasound followed by biopsy). One hundred sixty-three women were diagnosed 
with breast cancer. There was a paradoxical increase in the re-excision rate in the 
MRI group (34%) and no difference in conversion to mastectomy (11%) compared 
with the re-excision rate in the non-MRI group (12%, P = .008) and conversion to 
mastectomy (14% P = .49).
9. Preoperative evaluation of axilla in diagnosed breast cancer
Ultrasound is the primary imaging technique to evaluate morphological abnor-
malities in the lymph nodes. It is a moderately sensitive method (between 26 and 
80%) and can be very specific (ranges from 88 to 98%) [72, 73] when a morphologi-
cal sign that indicates alterations is used as a diagnostic criterion such as general 
shape, the aspect of the cortex, the hilum and vascularization, rather than size 
[72–74]. A normal axillary lymph node sizes less than 10 mm, has a smooth and well-
defined contour with an echogenic hilum (constitutes the majority of the node), and 
is surrounded by a thin and uniform hypoechoic cortex measuring less than 3 mm 
[75]. The ultrasound aspects of tumor infiltration in a crescent order of specificity 
are diffuse cortical thickening (> 3 mm); focal cortical bulge; eccentric cortical 
thickening; rounded hypoechoic node; partial or complete effacement of the fatty 
hilum; non-hilar blood flow on color Doppler; partial or total replacement of the 
node with an ill-defined (or irregular mass) and microcalcifications in the node [76]. 
The last step of the tumoral infiltration is spread to the perinodal fat [74, 76–78].
Axillary Ultrasound (AUS) and needle biopsy of abnormal-appearing nodes 
can appropriately allocate a positive predictive value for detecting nodal metastases 
[79, 80]. The use of ultrasound and biopsy in an abnormal lymph node improves 
sensitivity (88% vs. 61%), specificity (100% versus 85%), positive predictive value 
(91% versus 73%), and negative predictive value (100% versus 77%) compared to 
US alone [73–75]. The approach for identifying axillary metastases in women with 
T1 or T2 invasive breast cancer ranges from axillary imaging only in patients with 
suspicious findings (from physical examination of the axilla) [74] to axillary imaging 
being performed in all patients [5–7]. The identification of axillary disease on preop-
erative ultrasound was considered a reliable indicator for preoperative identification 
of axillary metastases, allowing the surgeon to proceed directly to axillary lymph 
node dissection (ALND) and omission of sentinel lymph nodes biopsy (SNB) [81].
However, the clinical utility of preoperative axillary imaging evaluation in 
women with T1 or T2 invasive breast cancer has changed with the American College 
of Surgeons Oncology Group (ACOSOG) Z0011 study [82] and International Breast 
Cancer Study Group (IBCSG)23–01 [83]. These randomized controlled trials have 
established that women with clinical T1–2 invasive breast carcinoma and clinically 
negative axilla with 1–2 positive sentinel lymph nodes (SLNs) can safely spare 
ALND without impacting overall survival, disease-free survival, or locoregional 
recurrence. Hence, several studies have attempted to evaluate whether it can man-
age patients without palpable adenopathy but with positive axillary nodes identified 
by ultrasound according to Z0011 criteria [84–87]. These studies have reported 
that between 43% and 51.9% of patients with nodal metastases on imaging had 
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pN1 disease at surgery, suggesting that a cohort of patients with axillary metastases 
detected by imaging alone can be candidates for the omission of ALND based on 
minimal nodal disease. Although a considerable percentage of patients with image-
detected positive nodes have pN1 disease, multiple abnormal lymph nodes on 
axillary imaging were associated with a high likelihood of having pN2–3 disease and 
worse survival [88–90]. Axillary ultrasound seems to be more suited to exclude high 
axillary burden than quantifying the nodal disease volume in the event of abnormal 
axillary lymph nodes detected on preoperative axillary imaging.
In patients with clinically abnormal lymph nodes on physical exam, further 
evaluation of axilla with AUS with/without needle biopsy should consider appro-
priating to neoadjuvant chemotherapy, given the high nodal pathologic completed 
response (PCR) rates of 21 to 65% [91, 92]. Studies support the use of SNB for 
surgical staging of the axilla with false-negative rates of 8.4 to 14.2% [93–95]. 
Consequently, the de-escalation of axillary surgery for patients with metastatic 
axilla may not eliminate the need for the axillary US, but it certainly may make its 
use more selective.
10. Evaluation of the breast after surgical therapy
Breast imaging is a challenge in evaluating postoperative changes in breast 
cancer breast due to the wide range of imaging changes after surgery and the 
risk of recurrent disease. Ultrasound findings depending on the type of surgery 
performed: mastectomy, breast-conserving therapy, and breast reconstruction; 
whether radiation therapy has been performed; and the period elapsed from 
the end of treatment. Breast Ultrasound should perform in addition to, not as 
a replacement for, mammography [96, 97], for women who have undergone 
breast-conserving surgery and for the surgical site in patients with mastectomy. 
There are no post-mastectomy imaging guidelines since they are followed clini-
cally with serial physical examinations. In the absence of breast reconstruction, 
the chest wall, subcutaneous fat, and skin can be evaluated with ultrasonogra-
phy [98]. Cutaneous recurrence in patients after mastectomy may be palpable 
superficial mass.
Understanding the postsurgical imaging findings and their correlation is essen-
tial to ensure an accurate interpretation and recommendation. The most common 
changes in US imaging after breast-conserving surgery are:
• Skin thickening (more than 2 mm) and parenchymal edema, characterized 
by increased echogenicity and reticular enlargement of breast parenchyma 
(represented by dilated lymphatics or interstitial fluid). Those findings should 
start reducing six months after completing radiation therapy and returning to 
normal by two years of surgical treatment [99].
• Postsurgical scar or fibrotic dermal tissue after skin incision. Postsurgical scar 
appears as a discrete area of architectural distortion or hypoechoic interruption 
of the normal parenchyma with an irregular shape, not parallel orientation, 
strong acoustic shadowing, and absent vascularity. Fibrosis increases up to 
18 months and then stabilizes. Therefore, after that period, the tissue that 
enhances the distortion must be considered suspicious, and biopsy should be 
considered.
• Postoperative fluid collections in the surgical bed have variable echogenicity 
(hypoechoic, hyperechoic, or anechoic). The anechoic lesions have a thin wall, 
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sometimes with debris or septa. Hematomas may be ill-defined or present as 
a mass with distal acoustic enhancement or shadowing and internal complex 
echoes [10]. Postoperative fluid collection decreases by six months, though, in 
a few patients, these may persist for years [100].
• Fat necrosis appears as hypoechoic or heterogeneous irregular mass, with 
acoustic shadowing. These findings may be misinterpreted as suspicious for 
malignancy. Therefore, in this case, correlating mammographic findings and 
tissue sampling is indicated. (Figure 6)
11. Evaluation and assessment of the breast after medical therapy
Radiological and clinical evaluation of residual tumor size after neoadjuvant 
chemotherapy (NAC) is vital for decision-making in breast surgical planning. 
Physical examination, mammography, and ultrasound are not accurate in assessing 
the tumor response to NAC. Chagpar et al. [101] examined the accuracy of clinical 
methods of tumor size assessment (physical examination, mammography, and 
ultrasound) in evaluating the tumor response to chemotherapy. The correlation 
coefficients for residual tumor size were estimated for physical examination of 
0.42, ultrasound 0.42, and mammography 0.41. Interestingly, clinical measure-
ment estimated by each of these modalities in only 66–75% of cases was within one 
centimeter of the pathologic tumor size. Likewise, Peintinger et al. [102] showed 
higher accuracy (89%) with the combination of mammography and sonography 
in predicting pathological residual tumor size after neoadjuvant chemotherapy, 
but a moderate agreement (69% of patients) in predicting pathologic tumor size 
within 0.5 cm.
Therefore, breast ultrasound for clinical evaluation of tumor size is moderately 
useful for patients receiving chemotherapy first [7]. However, breast MRI has 
shown an equal or better correlation for these patients and offers the best per-
formance in assessing patients’ response and predicting pathological tumor size 
non-invasively [103, 104].
Figure 6. 
US Postoperative changes in Breast Conservation Treatment. (a) Parenchymal Edema, represented by reticular 
enlargement of breast parenchyma with dilated lymphatics (calipers) and interstitial fluid; (b) Postsurgical 
Scar, a discrete area of hypoechoic distortion with strong acoustic shadowing; (c) Postoperative Fluid Collection 
in surgical bed; (d) Fat Necrosis: Heterogeneous mass with acoustic shadowing.
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12. Intraoperative ultrasound (IOUS) in breast surgery
Intraoperative US (IOUS) is a non-invasive procedure that enables the surgeon 
to perform intraoperative localization and guided excision of a nonpalpable breast 
lesion, as well as ultrasound-guided operation of traditional palpation-guided 
surgery [105–109].
Widespread preoperative malignant lesion localization strategies for surgery 
are wire-guided localization (WGL) and radio occult lesion localization (ROLL)-
guided surgery to ensure the whole removal of imaging findings and allow margin 
clearance [110–112]. Rahusen et al. [110] reported that IOUS (89%) is superior to 
wire-guided surgery (55%) concerning tumor-free resection margins. A retrospec-
tive multicenter study [113] demonstrated that IOUS for nonpalpable invasive 
breast cancer was more accurate in obtaining adequate margins with the lowest rate 
of positive margins in the IOUS group (3.7%) than in the wire-localization group 
(21.3%) and radioguided occult lesion group (25%). Snider et al. showed a reason-
able rate of tumor-free resection margins using IOUS (82%) with a smaller excision 
volume of healthy breast tissue than wire-guided surgery [114].
A meta-analysis [111] of patients with nonpalpable breast cancer treated 
with IOUS vs. wire-guided localization (WGL) showed that the rate of involved 
surgical margins for IOUS varies 0–19%. There was a statistically significant 
difference between IOUS and WGL regarding tumor-free margins favoring IOUS 
(OR = 0.52; 95%CI: 0.38–0.71). In the meta-analysis of Pan et al. [112], IOUS is 
an accurate method for localizing nonpalpable and palpable breast cancers by 
obtaining a high proportion of negative margins and adequate resection vol-
umes in patients undergoing breast-conserving surgery. Thirteen studies were 
included. Eight were eligible for the impact of IOUS on the margin status of non-
palpable breast cancers; four were suitable for palpable breast cancers, and one 
was for both nonpalpable and palpable breast cancers. This meta-analysis showed 
a statistically significant increase in the rate of negative margins using IOUS for 
both nonpalpable and palpable breast cancers. IOUS-guidance enabled a signifi-
cantly higher negative margin rate for non-palpable breast cancers than WGL-
guidance (RR =1.26, 95% CI =1.09–1.46 from 6 prospective studies; OR = 1.45, 
95% CI =0.86–2.43 from 2 retrospective studies). For palpable breast cancers, 
the relative risk (RR) for IOUS associated negative margins was 2.36 (95% CI 
=1.26–4.43) in 2 prospective studies, and OR was 2.71 (95% CI = 1.25–5.87) in 2 
retrospective studies.
Breast surgeon-performed IOUS-guided excision does not depend on the 
radiology or nuclear medicine department. This procedure avoids the need for an 
additional localization procedure preoperatively, is non-stressful for the patients, 
and allows accurate intraoperative targeting and immediate confirmation of lesion 
removal with tumor-free margins. The use of this technique allocates hospital 
resources efficiently in resource-constraint contexts.
IOUS has demonstrated benefits in patients with palpable early-stage primary 
invasive breast cancer to completely excise the tumor with negative margins and 
small excision volumes, improving the result. COBALT-trial [107] was a multicenter 
randomized controlled trial for palpable cancer, comparing IOUS with palpation-
guided surgery (PGS). Results of this trial showed a difference in tumor-involved 
margin of 3% of tumor-involved margins for the invasive component in the 
IOUS-group compared to 17% in the PGS-group, and thus a significant decrease 
in additional treatment required in the IOUS group (2% re-excision and 9% boost 
in IOUS vs. 7% mastectomy, 4% re-excision and 16% boost in the PGS group). 
Furthermore, secondary results of this trial showed IOUS had smaller odds of hav-
ing worse cosmetic outcomes than PGS (OR = 0.51, P = 0.045).
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